ATE417041T1 - Neue farnesylproteintransferaseinhibitoren als antitumormittel - Google Patents

Neue farnesylproteintransferaseinhibitoren als antitumormittel

Info

Publication number
ATE417041T1
ATE417041T1 AT04779960T AT04779960T ATE417041T1 AT E417041 T1 ATE417041 T1 AT E417041T1 AT 04779960 T AT04779960 T AT 04779960T AT 04779960 T AT04779960 T AT 04779960T AT E417041 T1 ATE417041 T1 AT E417041T1
Authority
AT
Austria
Prior art keywords
transferas
inhibitors
tumor agents
farnesyl protein
new
Prior art date
Application number
AT04779960T
Other languages
English (en)
Inventor
Hugh Zhu
Alan Cooper
Jagdish Desai
James Wang
Dinanath Rane
Ronald Doll
F Njoroge
Viyyoor Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE417041(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE417041T1 publication Critical patent/ATE417041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04779960T 2003-08-07 2004-08-04 Neue farnesylproteintransferaseinhibitoren als antitumormittel ATE417041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49326903P 2003-08-07 2003-08-07
US49850903P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
ATE417041T1 true ATE417041T1 (de) 2008-12-15

Family

ID=34138747

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779960T ATE417041T1 (de) 2003-08-07 2004-08-04 Neue farnesylproteintransferaseinhibitoren als antitumormittel

Country Status (19)

Country Link
US (1) US7557107B2 (de)
EP (1) EP1660477B1 (de)
JP (1) JP2007501791A (de)
KR (1) KR20060057599A (de)
AR (1) AR045447A1 (de)
AT (1) ATE417041T1 (de)
AU (1) AU2004263493A1 (de)
BR (1) BRPI0413384A (de)
CA (1) CA2535210A1 (de)
DE (1) DE602004018332D1 (de)
EC (1) ECSP066349A (de)
ES (1) ES2317047T3 (de)
HK (1) HK1087122A1 (de)
IL (1) IL173514A0 (de)
MX (1) MXPA06001483A (de)
PE (1) PE20050336A1 (de)
RU (1) RU2006106768A (de)
TW (1) TW200510384A (de)
WO (1) WO2005014577A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
EP1506286B1 (de) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralisierung eines menschlichen anti-igfr-antikörpers
TW200412956A (en) * 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
EP1854465A1 (de) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Verwendung von 4,17 beta-dihydroxyandrost-4-ene-3-one zur Behandlung von Krebs
US20100111965A1 (en) * 2006-10-11 2010-05-06 Fusion Antibodies Limited Combination therapy
US8907095B2 (en) 2007-10-22 2014-12-09 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
EP2872161B1 (de) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol zur verwendung bei der behandlung von tyrosinkinaseinhibitor-resistenten malignomen bei patienten mit genetischen polymorphismen oder ahi1-dysregulierungen oder mutationen
EP2983674A4 (de) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutischer nutzen suboptimal verabreichter chemischer verbindungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
NZ326035A (en) 1995-12-22 2000-01-28 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO2001064199A2 (en) 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
TW200412956A (en) * 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
US20050059672A1 (en) 2005-03-17
BRPI0413384A (pt) 2006-10-17
PE20050336A1 (es) 2005-05-30
JP2007501791A (ja) 2007-02-01
RU2006106768A (ru) 2007-09-20
KR20060057599A (ko) 2006-05-26
AR045447A1 (es) 2005-10-26
WO2005014577A1 (en) 2005-02-17
IL173514A0 (en) 2006-07-05
MXPA06001483A (es) 2006-05-15
CA2535210A1 (en) 2005-02-17
HK1087122A1 (en) 2006-10-06
DE602004018332D1 (de) 2009-01-22
ECSP066349A (es) 2006-08-30
EP1660477A1 (de) 2006-05-31
US7557107B2 (en) 2009-07-07
WO2005014577A9 (en) 2006-03-23
TW200510384A (en) 2005-03-16
ES2317047T3 (es) 2009-04-16
EP1660477B1 (de) 2008-12-10
AU2004263493A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE354631T1 (de) Nuancierungsmittel
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DE602005020465D1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
DK1543038T4 (da) Proteinoprensning
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE537843T1 (de) Neue kinase-hemmer
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
DE502004003292D1 (de) Flugzeug
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE450528T1 (de) Chinazolinderivate als antitumormittel
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DK1644002T3 (da) Multipartikler
DK1689775T3 (da) GAG-bindende proteiner
ATE417041T1 (de) Neue farnesylproteintransferaseinhibitoren als antitumormittel
ATE411306T1 (de) Biarylsulfonamide als mmp-inhibitoren
DK1809660T3 (da) Thymus-specifikt protein
DE502004006055D1 (de) 6-arylamino-5-cyano-4-pyrimidinone als pde9a-inhibitoren
NO20044053L (no) Farnesylproteintransferaseinhibitorer som antitumormidler
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60334907D1 (de) Neue phthalamidderivate
DE602004027594D1 (de) Triac

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties